Royal Bank Of Canada Moleculin Biotech, Inc. Transaction History

Royal Bank Of Canada

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	BUY	$0.41 - $0.86 $8,133 - $17,061	19,839 Added 6420.39%	20,148 $17,000
Q3 2023 Nov 14, 2023	SELL	$0.38 - $0.72 $253 - $480	-668 Reduced 68.37%	309 $0
Q2 2023 Aug 14, 2023	BUY	$0.54 - $0.95 $527 - $928	977 New	977 $0
Q3 2022 Nov 14, 2022	BUY	$1.15 - $1.9 $293 - $484	255 New	255 $0

3.35K

Ticker MBRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 28,606,700
Market Cap $124M
Description
Moleculin Biotech, Inc., a clinical-stage pharmaceutical company, focuses on the development of drug candidates for the treatment of highly resistant tumors and viruses. Its lead drug candidate is Annamycin that is in Phase 1/2 studies for the treatment of relapsed or refractory acute myeloid leukemia (AML) and cancers metastasized to the lungs....

Get notified when there are updates to the investment portfolio of Royal Bank Of Canada, based on Form 13F filings with the SEC.

Stay updated on Royal Bank Of Canada with notifications on news.